NRIX vs PATH
Nurix Therapeutics Inc (NRIX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported NRIX revenue for 2024-11-30 was $54.5M. Net income was -$193.6M. Revenue was down 29.1% from 2023-11-30 to 2024-11-30. NRIX currently screens at market cap $1.77B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
NRIX currently screens at market cap $1.77B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the NRIX and PATH stock pages for the full models.
Not investment advice.